EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Regenerx Biopharmaceuticals's Enterprise Value is $1.40 Mil.
Regenerx Biopharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2023 was $-1.36 Mil. Therefore, Regenerx Biopharmaceuticals's EV-to-EBIT for today is -1.02.
The historical rank and industry rank for Regenerx Biopharmaceuticals's EV-to-EBIT or its related term are showing as below:
RGRX's EV-to-EBIT is not ranked *
in the Biotechnology industry.
Industry Median: 8.05 * Ranked among companies with meaningful EV-to-EBIT only.
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Regenerx Biopharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2023 was $16.47 Mil.
Regenerx Biopharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2023 was $-1.36 Mil. Regenerx Biopharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2023 was -8.28%.
Regenerx Biopharmaceuticals EV-to-EBIT Historical Data
The historical data trend for Regenerx Biopharmaceuticals's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Regenerx Biopharmaceuticals's EV-to-EBIT
For the Biotechnology subindustry, Regenerx Biopharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regenerx Biopharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regenerx Biopharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Regenerx Biopharmaceuticals's EV-to-EBIT falls into.
Regenerx Biopharmaceuticals's current Enterprise Value is $1.40 Mil.
Regenerx Biopharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.36 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Regenerx Biopharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2023 was $16.47 Mil.
Regenerx Biopharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.36 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regenerx Biopharmaceuticals EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Regenerx Biopharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Regenerx Biopharmaceuticals (Regenerx Biopharmaceuticals) Business Description
Regenerx Biopharmaceuticals Inc is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Its operations are confined to one business segment: the development and marketing of product candidates based on Thymosin Beta 4 (Tß4), an amino acid peptide. The company has formulated Tß4 into three distinct product candidates in clinical development: RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology; RGN-137, a topical gel for dermal wounds and reduction of scar tissue; and RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RGRX has been successfully added to your 